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A Quantitative Analysis of Colonic Mucosal Oxylipins and 
Endocannabinoids in Treatment-Naïve and Deep Remission 
Ulcerative Colitis Patients and the Potential Link With Cytokine 
Gene Expression
Joseph Diab, MSc,* Rania Al-Mahdi, PhD,† Sandra Gouveia-Figueira,PhD,‡ Terkel Hansen, PhD,*  
Einar Jensen, PhD,* Rasmus Goll, PhD,† Thomas Moritz, PhD,‡ Jon Florholmen, PhD,† and Guro Forsdahl, PhD*
Background: The bioactive metabolites of omega 3 and omega 6 polyunsaturated fatty acids (ω-3 and ω-6) are known as oxylipins and endo-
cannabinoids (eCBs). These lipid metabolites are involved in prompting and resolving the inflammatory response that leads to the onset of 
inflammatory bowel disease (IBD). This study aims to quantify these bioactive lipids in the colonic mucosa and to evaluate the potential link to 
cytokine gene expression during inflammatory events in ulcerative colitis (UC).
Methods: Colon biopsies were taken from 15 treatment-naïve UC patients, 5 deep remission UC patients, and 10 healthy controls. Thirty-five 
oxylipins and 11 eCBs were quantified by means of ultra-high-performance liquid chromatography coupled with tandem mass spectrometry. 
Levels of mRNA for 10 cytokines were measured by reverse transcription polymerase chain reaction.
Results: Levels of ω-6-related oxylipins were significantly elevated in treatment-naïve patients with respect to controls, whereas the levels of 
ω-3 eCBs were lower. 15S-Hydroxy-eicosatrienoic acid (15S-HETrE) was significantly upregulated in UC deep remission patients compared with 
controls. All investigated cytokines had significantly higher mRNA levels in the inflamed mucosa of treatment-naïve UC patients. Cytokine gene 
expression was positively correlated with several ω-6 arachidonic acid–related oxylipins, whereas negative correlation was found with lipoxin, 
prostacyclin, and the eCBs.
Conclusions: Increased levels of ω-6-related oxylipins and decreased levels of ω-3-related eCBs are associated with the debut of UC. This high-
lights the altered balance between pro- and anti-inflammatory lipid mediators in IBD and suggests potential targets for intervention.
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INTRODUCTION
 Inflammatory bowel disease (IBD) is a chronic, relapsing 
inflammatory disorder in the gastrointestinal tract that affects 
up to 0.5% of the population of the Western world.1 The 2 
major forms of IBD, ulcerative colitis (UC) and Crohn’s dis-
ease (CD), are characterized by a dysregulated mucosal immune 
response triggered by intestinal commensal flora.2 The onset of 
IBD symptoms appears to be caused by an imbalance between 
pro- and anti-inflammatory molecules.3 However, several factors 
might be involved in the chronic inflammatory state observed 
in IBD. These include cytokines, interleukins (ILs), nitric oxide 
(NO), free radicals, activated Toll-like receptors, oxylipins, and 
microbiota.3 Furthermore, it has previously been shown that 
colitis is associated with a disruption in the lipid metabolism.4
Oxylipins are bioactive derivatives mainly from 
omega 3 and omega 6 polyunsaturated fatty acids (ω-3 
and ω-6 PUFAs) such as ω-6 arachidonic acid (AA), ω-6 
linoleic acid (LA), ω-3 eicosapentaenoic acid (EPA), and 
ω-3 docosahexaenoic acid (DHA).5 Oxylipins are synthe-
tized through 3 main enzymatic pathways, namely cycloox-
ygenase (COX), lipoxygenase (LOX), and cytochrome P450 
(CYP450), resulting in more than 100 active mediators. 
The AA-derived oxylipins, also known as eicosanoids, are 
involved in chemotaxis and promoting the recruitment of 
neutrophils to the site of  inflammation. The role of  oxylipins 
in IBD is very complex and not completely understood; for 
example, prostaglandin E2 (PGE2) induces epithelial prolif-
eration in response to mucosal damage and suppresses the 
release of  tumor necrosis factor (TNF) from macrophages.6 
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Leukotriene B4 (LTB4) has chemotactic effects by stimu-
lating leucocyte activation and adhesion to the vascular 
endothelium and promotes the production of  inflammatory 
cytokines.7 Furthermore, inflammation-resolving oxylipins 
termed resolvins, lipoxins, protectins, and maresins are pro-
duced from AA, EPA, and DHA.8
The endocannabinoids (eCBs) are a family of bioactive 
lipids that are biosynthesized from membrane glycerophospho-
lipids and bind to cannabis receptors (CB), specifically, CB1 
and CB2.9 The primary eCBs are arachidonoyl ethanolamine, 
known as anandamide (AEA), and 2-arachidonoylglycerol 
(2-AG). The secondary or “atypical” eCBs, such as docohex-
aenoic ethanolamine (DHEA) and eicosapentaenoyl ethanol-
amide (EPEA), play an important synergetic role to AEA.10 
CB1 receptors are highly expressed in several brain regions that 
mediate the psychoactive effects of cannabinoids, whereas CB2 
receptors are found in a number of immune cells and in a few 
neurons.11 It has been shown that eCBs regulate immune homeo-
stasis in the gut–pancreas axis. For instance, eCBs inhibit the 
release of a wide class of pro-inflammatory mediators, including 
IL-1β, TNF, and NO.9, 12 Some studies have reported changes 
in endocannabinoid system expression during UC.13 However, a 
previous targeted analysis of eCBs in inflamed mucosa in IBD 
was inconclusive and was restricted to ω-6 AA derivatives.14–17
A quantitative analysis of all bioactive lipid metabo-
lites in UC colon biopsies is needed to fully understand their 
involvement in promoting and resolving the inflammatory 
event in IBD. Therefore, in this study, we have quantified 35 
nonesterified oxylipins and 11 eCB metabolites (Supplementary 
Table 1) simultaneously in colon biopsies taken from 3 differ-
ent groups, namely treatment-naïve UC patients in the debut of 
the disease, deep remission UC patients, and healthy subjects. 
We have further analyzed the cytokine profile in colon biopsies 
from the same patients to evaluate a potential link between the 




Mucosal biopsies were collected from newly diagnosed 
treatment-naïve UC patients and UC patients in deep remis-
sion. UC diagnosis was established based on clinical, endo-
scopic, and histological criteria defined by European Crohn’s 
and Colitis Organization (ECCO) guidelines.18 Furthermore, 
the degree of inflammation was evaluated during colonos-
copy using the scoring system of the Ulcerative Colitis Disease 
Activity Index (UCDAI).19 Moreover, TNF mRNA levels were 
measured by real-time reverse transcription polymerase chain 
reaction (RT-PCR) to assess the level of UC activity.20 Deep 
remission was defined by endoscopically healed mucosa (Mayo 
score  =  0) and a normalized mucosal TNF gene expression 
level induced by anti-TNF treatment.21 Subjects admitted for 
a cancer screening and with normal colonoscopy histological 
findings served as healthy controls. None of the recruited sub-
jects suffered from irritable bowel syndrome, and they were not 
taking nonsteroidal anti-inflammatory drugs (NSAIDs) before 
the colonoscopy. The patients in deep remission were on regu-
lar UC medications including 5-aminosalicylic acid (5-ASA), 
azathioprine, and anti-TNF. From each study participant, 2 
adjacent biopsies were obtained from the inflamed mucosa, 
and 1 biopsy was immediately immersed in RNAlater (Qiagen, 
Hilden, Germany). The second biopsy was immediately frozen 
in a dry cryotube tube at –70°C. The biopsies from both UC 
patients and the UC remission group were obtained from the 
rectum or sigmoid colon, whereas biopsies from the control 
group were obtained from the rectum area only. The dry weight 
of the biopsies ranged from 2 to 8 mg. All biopsies were kept at 
–70°C until further analysis.
Chemical and Reagents
The eCB analytical standards, the oxylipin analytical 
standards, and 12- (cyclohexylamino)carbonyl[amino]-dodeca-
noic acid (CUDA) were purchased from Cayman Chemicals 
(Ann Arbor, MI, USA). Acetonitrile (ACN) and methanol 
(MeOH) were acquired from Merck (Darmstadt, Germany). 
Isopropanol was obtained from VWR PROLABO (Fontenay-
sous-Bois, France). Acetic acid was purchased from Aldrich 
Chemical Company, Inc. (Milwaukee, WI, USA). All solvents 
were of HPLC grade or higher. Water was purified by a Milli-Q 
Gradient system (Millipore, Milford, MA, USA). Oasis HLB 
cartridges (3 cc, 60 mg) were obtained from Waters (Milford, 
MA, USA).
Endocannabinoid and Oxylipin Quantification
Analysis of eCBs and nonesterified oxylipins was per-
formed by a previously published method.22 Briefly, 500  μL 
of methanol and a tungsten bead were added to each sam-
ple; the samples were then mixed in Qiagen plates (Qiagen, 
Valencia, CA, USA) for 3 minutes at a speed of 30 Hz. After 
removing the beads, the samples were centrifuged for 3 minutes 
at a speed of 14,000  rpm (2125  × g) and +4°C. The metab-
olites were extracted by a solid phase extraction (SPE) pro-
tocol described elsewhere.23 In brief, the samples were spiked 
with 10 μL of the following internal standard solution: 50 ng/
mL 12,13-DiHOME-d4 and 12,13-EPOME-d4, 25  ng/mL 
9-HODE-d4, PGE2-d4, 5-HETE-d8, 20-HETE-d6 and TXB2-d4, 
800 ng/mL 2-AG-d8, 40 ng/mL PGF2α-EA-d4 and PGE2-EA-d4, 
20  ng/mL AEA-d4, OEA-d4, and SEA-d3. Then, the samples 
were applied to the SPE columns and washed by a mix of 5% 
MeOH and 0.1% acetic acid, before eluting the metabolites with 
3 mL of ACN and 2 mL of MeOH. Finally, the samples were 
dried using a vacuum concentrator (MIVac, SP, Warminster, 
PA, USA), reconstituted in 100 µL of MeOH, and spiked with 
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analysis was conducted using an Agilent UPLC system (Infinity 
1290) coupled with an electrospray ionization source (ESI) to 
an Agilent 6490 triple quadrupole system equipped with iFun-
nel Technology (Agilent Technologies, Santa Clara, CA, USA). 
Metabolite separation was performed using a Waters BEH C18 
column (2.1 mm × 150 mm, 130 Å, 1.7-μm particle size). A flow 
rate of 300 μL/min and 10-μL injection volume were employed 
for each run. Separate injections were used for subsequent ion-
ization in positive (eCB) and negative (oxylipin) mode. The 
mobile phase consisted of (1) 0.1% acetic acid in MilliQ water 
and (2) acetonitrile:isopropanol (90:10). The gradient and ESI 
applied conditions were optimized and have been described 
elsewhere.23 MassHunter Workstation software was used to 
control the instrument and to integrate all peaks manually.
An 8-point calibration curve was constructed using pure 
standards. Furthermore, the recovery of each internal standard 
was calculated by adding the recovery standard CUDA to each 
sample as quality control.
Quantification of Cytokine mRNA Using 
Real-time PCR
Total RNA was isolated from patient biopsies using the 
Allprep DNA/RNA Mini Kit (Qiagen, Hilden, Germany, Cat 
No: 80204) and the automated QIAcube instrument (Qiagen, 
Hilden, Germany) according to the manufacturer’s recom-
mendations. Quantity and purity of the extracted RNA were 
determined using the Qubit 3 Fluorometer (Cat No: Q33216; 
Invitrogen by Thermo Fisher Scientific, Waltham, MA, USA). 
Reverse transcription of the total RNA was performed using 
the QuantiTect Reverse Transcription Kit (Cat. No: 205314; 
Qiagen, Hilden, Germany). Levels of mRNA for IL-1β, IL-4, 
IL-5, IL-6, IL-10, IL-12, IL-17, IL-23, IFN-γ, TNF, and the 
housekeeping gene β-actin were quantified by a previously pub-
lished method.24 The primers and probe sequences are shown 
in Supplementary Table  3. Cytokine mRNA expression was 
reported according to the ∆CT and ∆∆CT method described by 
Schmittgen, with fold change as 2-∆∆CT.25 For the TNF assay, we 
used an in-house absolute standard based on a serially diluted 
PCR product. By using this standard curve, we derived a copy 
number per μg of total RNA for each sample.
Statistical Analysis
The concentration of each metabolite was normalized by 
sample weight, and the results were reported as pg/mg of colon 
tissue. Statistical analysis was carried out using MetaboAnalyst 
3.0, a web tool for metabolomics data analysis (http://www.
metaboanalyst.ca/).26 Two samples had extremely low and high 
concentrations (below/higher than the mean plus/minus 3 stan-
dard deviations) of 60% of the metabolites and were consequently 
excluded. One percent of reported metabolites were below the 
level of detection. Therefore, they were replaced by a small value 
(half of the minimum positive value in the original data).
First, metabolite concentrations were autoscaled to 
reduce differences in magnitude.27 Second, the Shapiro-Wilk 
test for normality was run. The data were found to be non–
normally distributed, and nonparametric univariate analy-
sis (Mann-Whitney U test) was performed. Differences in the 
mean concentration of metabolites between the study groups 
were identified at a fold change (FC) of 2 and a false discov-
ery rate (FDR; Benjamini Hochberg) cutoff  of 0.1, as previ-
ously described.28 The 2-FC cutoff was chosen to minimize the 
effects of biological variation, whereas the FDR cutoff was set 
to 0.1 due to the exploratory nature of our study, and the low 
risk of reporting false positivity. Finally, significant variation 
in the metabolite concentrations among the 3 study groups was 
detected by Kruskal-Wallis nonparametric analysis of vari-
ance. For multiple testing correction, acquired P values were 
adjusted using the Benjamini and Hochberg method. Adjusted 
P values <0.05 were considered significant.
Frequency distribution analysis and tests of normality 
(Shapiro Wilk) were run on ΔCT values from RT-PCR analy-
ses. The data were found to be normally distributed, and cyto-
kine gene expression differences between the study groups were 
compared using a 2-tailed Student t test. To account for the 
multiple group testing, acquired P values were adjusted by the 
Dunett post hoc test. Adjusted P values <0.05 were considered 
significant.
Pair-wise Spearman’s rank correlation coefficients 
between metabolites, transcripts, and between metabolites and 
transcripts (autoscaled values) were computed and are pre-
sented in a heatmap. This was done using RStudio: Integrated 
Development Environment (version 1.0.143); and R package 
“corrplot”: Visualization of a Correlation Matrix (version 0.84; 
https://github.com/taiyun/corrplot).
Ethical Considerations
The Regional Committee of Medical Ethics of North 
Norway and the Norwegian Social Science Data Services 
approved the study and the storage of biological material under 
the number REK NORD 2012/1349. In addition, all enrolled 
subjects have signed an informed written consent.
RESULTS
Subjects Characteristic
In total, 15 newly diagnosed treatment-naïve UC patients 
with mild to severe disease activity, 5 UC patients in deep remis-
sion, and 10 healthy controls were enrolled in this study. The 
study group characteristics are described in Table 1. Ulcerative 
colitis patients’ disease activity ranged from mild to severe; a 
UCDAI score of 3 to 6 was defined as mild, 7 to 10 as moderate, 
and 11 to 12 as severe UC. Accordingly, 7 patients had mild UC, 
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Mucosal eCB and Oxylipin Profiles in Treatment-
Naïve UC Patients, UC Remission Patients, and 
Controls
The concentrations of eCBs and oxylipins in colon biopsies 
from treatment-naïve UC and deep remission UC patients were 
compared with controls. As seen in Figure 1A, the volcano plot 
shows that the mucosal levels of PGE2, thromboxane (TXB2), 
trans- leukotriene (trans-LTB4), and 12-Hydroxy-eicosatetraenoic 
acid (12-HETE) were significantly upregulated (FDR ≤ 0.1) in 
colon biopsies taken from treatment-naïve patients. The mean 
concentrations of these oxylipins were increased by 7-, 3-, 8-, and 
5-fold, respectively. In contrast, DHEA and EPEA were signifi-
cantly downregulated. The mean concentration was decreased by 
3-fold for both eCBs, with respect to the control group.
The comparison between the mucosal concentration of 
the investigated metabolites in deep remission UC patients 
and healthy controls is demonstrated in Figure  1B. Only 
15Ss-Hydroxy-eicosatrienoic acid (15s-HETrE) was signifi-
cantly upregulated by 2-fold in deep remission UC patients 
compared with healthy controls.
Furthermore, the Kruskal-Wallis test was used to com-
pare the metabolite mucosal profiles between all 3 groups, as 
shown in Figure 2A. The metabolites that showed significant 
variance between the study groups were 1  ω-3 eCB, specif-
ically DHAE (Fig.  1D, C), and 1  ω-6 AA oxylipin, specifi-
cally HETE-12 (Fig. 1D). The mean concentration of  DHAE 
decreased in a stepwise manner from UC-naïve treatment 
patients to UC remission patients and controls. In contrast, 
the concentration of  HETE-12 was the highest in the treat-
ment-naïve UC group.
Mucosal Cytokine Gene Expression in Treatment-
Naïve UC Patients, UC Remission Patients, and 
Controls
Cytokine gene expression in colon biopsies was inves-
tigated by the quantification of mRNA using real-time PCR. 
Comparative analysis of mean differences in the cytokine 
gene expression levels between treatment-naïve UC patients, 
UC remission patients, and controls was done by Student t 
test. The results are shown in Table  2. All investigated cyto-
kines had significantly higher mRNA levels in the inflamed 
mucosa of treatment-naïve UC patients compared with healthy 
controls. However, IL-5 did not differ significantly (P = 0.057). 
Furthermore, no significant differences were found in the gene 
expression of all investigated cytokines between the UC remis-
sion group and healthy controls (Table 2).
Cytokine Gene Expression Correlation With 
Oxylipins and eCBs
To assess the association between cytokine gene expres-
sion and the investigated metabolites in the mucosal biopsies 
of the study groups, Spearman’s rank correlation between 
cytokines-cytokines and cytokines-metabolites was computed 
and is presented as an asymmetric heatmap (Fig. 2), where red 
represents a positive correlation and blue a negative correla-
tion. All investigated cytokines were positively correlated with 
each other. Furthermore, the cytokines were found to be nega-
tively correlated with several eCBs, mainly EPEA and DHEA 
(r ≈ –0.4). In contrast, the cytokines were positively correlated 
with nearly all AA metabolites, specifically PGE2, 12-HETE, 
5-Hydroxy-eicosatetraenoic acid (5-HETE), TXB2, and LTB4 (r 
≈ 0.5). However, there was a negative correlation with lipoxin 
(LXA4) and α-Keto prostaglandin F1 (α-keto PGF1), as shown 
in Figure  2. Furthermore, the correlation matrix revealed a 
negative correlation between cytokines and ω-6 AA–derived 
vicinal diols (DHETs) and a positive correlation with ω-6 AA–
derived epoxides (EpETrEs).
Spearman’s rank correlation coefficients were computed 
for metabolites-metabolites, cytokines-cytokines, and cyto-
kines-metabolites and are represented as a symmetric heatmap 
(Supplementary Fig. 1). In addition, the correlation coefficients 
and the significance P values corresponding to all computed 
correlations are provided in the Supplementary Data.
DISCUSSION
This study provides a unique, quantitative, and com-
prehensive analysis of a large number of oxylipins and eCBs 
in the colon mucosa of treatment-naïve newly diagnosed UC 
patients and deep remission UC patients. Previous studies were 
restricted to investigating oxylipins related to selected enzy-
matic pathways (COX-2 and 5-LOX) in UC.29–31 Moreover, in 
these studies, oxylipins were determined by liquid chromatog-
raphy–tandem mass spectrometry (LC-MS/MS) untargeted 
analysis.32 For a more accurate quantification,33 we have quanti-
fied 35 oxylipin and 11 eCB metabolites using a fully validated 
TABLE 1: Description of Study Group Characteristics
Study Group No. Subjects
Age, Mean 
(Range), y Sex, Female/Male
UCDAI Score, 
Median (Range)
TNF-α, Mean (Range), Copies/μg of 
Total RNA
UC patients 15 37 (14–69) 6/9 9 (4–15) 15,207 (4300–44,600)
Healthy controls 10 68 (25–86) 4/6 — 3430 (1100–7900)
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FIGURE 1. Results from univariate analysis of oxylipin and eCB mean mucosal concentrations. A, B, Volcano plots of changes in mean mucosal con-
centrations of oxylipins and eCBs in treatment-naïve patients vs healthy controls (HCs), and UC deep remission patients vs HCs, respectively. The 
vertical lines correspond to 2.0-fold up- and downregulation, and the horizontal lines represent a P value of 0.05 (Mann-Whitney U test) at a cutoff 
FDR value of 0.1. The points in the plots represent metabolite mean concentrations. Metabolites in pink have passed the volcano plot filtering. C, D, 
Box plots of the autoscaled concentration of DHEA and 12-HETE, respectively. The mean concentrations of these metabolites were found to have 
significantly changed among the study groups according to Kruskal-Wallis analysis of variance.
FIGURE 2. Colored heatmap of the pair-wise Spearman’s rank correlation coefficients computed for cytokines vs cytokines, cytokines vs eCBs, and 
cytokines vs oxylipins. The colors refer to the correlation coefficient direction and magnitude, ranging from –1 (blue) to 1 (red). Each box in the heat-
map is constructed from the metabolites-cytockines data of the 28 enrolled subjects. The metabolites are ordered according to the corresponding 
PUFA and the metabolic pathway. The correlation coefficients and the significance P values corresponding to all computed correlations are provided 
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targeted high-performance LC-MS/MS method. In addition, 
previously published studies were performed on a mix of treated 
and treatment-naïve UC patients,29–31 which might be a limita-
tion. Therefore, in this study, only treatment-naïve patients 
were included in the active UC group (Table 1). Moreover, the 
deep remission patients were selected based on their endoscopy 
scores and TNF measurement results.
Our findings suggest that inflammation of  the colonic 
mucosa in UC at debut is associated with a significant eleva-
tion in concentrations of  ω-6 AA–related oxylipins, specif-
ically, PGE2, TXB2, trans-LTB4, and 12-HETE, in addition 
to lower concentrations of  ω-3 eCBs (DHEA and EPEA) 
(Fig.  1). The ω-6 AA–related oxylipins are potent immune 
response regulators. For example, PGE2, produced via COX 
within the AA cascade, has a pro-inflammatory effect via IL-6 
production and dendritic cell activation and an anti-inflamma-
tory effect via local Treg-cell accumulation and lipoxin induc-
tion.32, 34 Moreover, 12-HETE, produced via 12-LOX within 
the AA cascade, is a potent chemoattractant for neutrophils.35 
In addition, LTB4 and its isomer trans-LTB4 stimulate the neu-
trophil chemotaxis in UC.36 Furthermore, TXB2 is the stable 
downstream metabolite of  thromboxane A2 (TXA2), which is 
known for causing vasoconstriction, platelet aggregation, and 
T-cell activation.37 Studies on ω-6 and ω-3 PUFAs and their 
bioactive lipid metabolites in IBD patients have revealed an 
alteration in their mucosal levels.5, 32, 38 To our knowledge, our 
study is the first to report alterations in EPEA and DHAE lev-
els in colonic mucosa in UC.
Interestingly, our data showed differences in the oxylipin 
profiles between deep remission patients and healthy controls. 
The ω-6-related oxylipin 15s-HETrE was significantly higher 
in the UC deep remission group in comparison with the con-
trol group, whereas the other investigated lipid metabolites did 
not differ significantly. Studies suggest that 15s-HETrE has an 
anti-inflammatory role via suppressing COX-2 overexpression39 
and inhibiting platelet reactivity and thrombosis.40 The UC 
remission patients enrolled in this study, however, had com-
pletely resolved inflammation in the colonic mucosa. Higher 
levels of 15(s)-HETrE could indicate the importance of this 
anti-inflammatory oxylipin in maintaining the state of remis-
sion. However, due to the low number of patients, this finding 
was not conclusive, and a further confirmatory study is needed.
We also investigated cytokine gene expression to have an 
overview of the association between cytokine production at the 
transcriptomic level and the lipid mediators at the metabolomic 
level. This allows a deeper interpretation of the variation in the 
eCB and oxylipin profiles. As our study is purely descriptive, we 
were more interested in describing the direction and degree of 
correlation than the statistical significance.
The gene expression of all investigated cytokines was 
higher in debut patients compared with healthy controls. This 
finding is in agreement with previous studies.24, 41–43 Interestingly, 
cytokine gene expression was positively correlated with 
AA-related oxylipins, except for LXA4 and α-keto PGF1, where 
a negative correlation was found (Fig. 2). These 2 oxylipins play 
an important anti-inflammatory role. For instance, α-keto PGF1 
is a stable metabolite of prostacyclin (PGI2),
44 which inhibits 
platelet activation and reduces the intensity of the inflammatory 
response.45 LXA4 is a potent inflammation resolution oxylipin 
that promotes the clearance of apoptotic cells by macrophages 
and limits the infiltration of pro-inflammatory leukocytes.46 
In fact, an LXA4 analog was found to inhibit TNF and IL-2 
mucosal expression in induced colitis in mice.47 Accordingly, 
increasing the levels of LXA4 and PGI2 may represent promis-
ing targets for intervention. Our data also revealed imbalances 
in the CYP pathway (Fig. 2), namely between the anti-inflam-
matory EpETrEs and the pro-inflammatory DHETs. This has 
previously been studied in obesity-induced colonic inflamma-
tion48 but needs to be further explored in IBD.
In contrast to AA-related oxylipins, the correlation matrix 
revealed a negative correlation between the cytokine profiles 
and the eCB profile, in particular regarding EPEA and DHEA. 
Therefore, our findings suggest a potential role of ω-3-derived 
eCBs in the resolution of inflammation, and we propose novel 
therapeutic targets. Cannabinoid agonists and endocanna-
binoid degradation inhibitors in rodent models of IBD have 
identified a potential therapeutic role for eCBs.14, 49 Recently, 
a potential anti-inflammatory role for EPEA and DHEA was 
suggested.50 This is through the epoxide forms (EEQ-EA and 
EDP-EA), which inhibit the production of the pro-inflamma-
tory cytokine IL-6 and promote the anti-inflammatory cytokine 
























IL-1β 7.88 1.33 <0.001 0.88
IL-6 15.98 1.35 <0.001 0.88
IL-12A 3.35 0.79 0.0404 0.80
IFN 6.53 0.76 0.001 0.80
IL-4 4.58 1.29 0.008 0.95
IL-5 4.18 1.15 0.07 0.98
IL-17A 33.38 0.84 <0.001 0.76
IL-23A 4.26 0.73 0.001 0.35
IL-10 4.13 1.15 <0.001 0.54
TGF- β 1.94 1.17 0.009 0.82
aMean fold change with respect to controls.
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IL-10.50 However, studies on the effectiveness of ω-3 supple-
mentation in the prevention and treatment of UC have been 
inconlusive and have failed to establish daily recommended 
intake.51, 52 In contrast, a trial study aiming to restore the lipid 
signaling balance in the intestinal tract by alkaline sphingo-
myelinase (Alk-SMase) rectal installation found significantly 
reduced inflammation and TNF expression.9
The small sample size in our study precludes subgroup 
analysis according to the severity of the disease in the UC treat-
ment-naïve group. In addition, the healthy control group was 
considerably older than the 2 UC groups, which might affect 
our results. Furthermore, the small size of the UC remission 
group, which only consisted of males, is considered a weakness 
in this study. Due to the imbalanced distribution in the ana-
lyzed cohort, the effects of both sex and age were not included 
in our data analysis. Therefore, our findings are exploratory 
and need to be validated in a larger cohort, in which, prefer-
ably, only sex- and age-matched healthy controls are included. 
This approach might give normally distributed data, and thus 
allow for the use of parametric statistical tests, which have more 
statistical power.
CONCLUSIONS
We demonstrated for the first time that the onset of UC 
is associated with increased levels of ω-6-related oxylipins and 
decreased levels of ω-3-related eCBs. Furthermore, we have 
revealed an association between bioactive lipid mediators and 
pro- and anti- cytokine production. Our findings highlight the 
mucosal fingerprints of the metabolism of PUFAs, which may 
be involved in the progression of inflammation and may be 
considered as potential targets for intervention that need to be 
explored in more detail in a larger study.
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